Literature DB >> 25449596

Polyoxometalates--potent and selective ecto-nucleotidase inhibitors.

Sang-Yong Lee1, Amelie Fiene1, Wenjin Li1, Theodor Hanck1, Konstantin A Brylev2, Vladimir E Fedorov2, Joanna Lecka3, Ali Haider4, Hans-Jürgen Pietzsch5, Herbert Zimmermann6, Jean Sévigny3, Ulrich Kortz4, Holger Stephan5, Christa E Müller7.   

Abstract

Polyoxometalates (POMs) are inorganic cluster metal complexes that possess versatile biological activities, including antibacterial, anticancer, antidiabetic, and antiviral effects. Their mechanisms of action at the molecular level are largely unknown. However, it has been suggested that the inhibition of several enzyme families (e.g., phosphatases, protein kinases or ecto-nucleotidases) by POMs may contribute to their pharmacological properties. Ecto-nucleotidases are cell membrane-bound or secreted glycoproteins involved in the hydrolysis of extracellular nucleotides thereby regulating purinergic (and pyrimidinergic) signaling. They comprise four distinct families: ecto-nucleoside triphosphate diphosphohydrolases (NTPDases), ecto-nucleotide pyrophosphatases/phosphodiesterases (NPPs), alkaline phosphatases (APs) and ecto-5'-nucleotidase (eN). In the present study, we evaluated the inhibitory potency of a series of polyoxometalates as well as chalcogenide hexarhenium cluster complexes at a broad range of ecto-nucleotidases. [Co4(H2O)2(PW9O34)2](10-) (5, PSB-POM142) was discovered to be the most potent inhibitor of human NTPDase1 described so far (Ki: 3.88 nM). Other investigated POMs selectively inhibited human NPP1, [TiW11CoO40](8-) (4, PSB-POM141, Ki: 1.46 nM) and [NaSb9W21O86](18-) (6, PSB-POM143, Ki: 4.98 nM) representing the most potent and selective human NPP1 inhibitors described to date. [NaP5W30O110](14-) (8, PSB-POM144) strongly inhibited NTPDase1-3 and NPP1 and may therefore be used as a pan-inhibitor to block ATP hydrolysis. The polyoxoanionic compounds displayed a non-competitive mechanism of inhibition of NPPs and eN, but appeared to be competitive inhibitors of TNAP. Future in vivo studies with selected inhibitors identified in the current study are warranted.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alkaline phosphatase; Ecto-5′-nucleotidase; Ecto-nucleotidase inhibitor; NPP1; NTPDase1; Polyoxometalate

Mesh:

Substances:

Year:  2014        PMID: 25449596     DOI: 10.1016/j.bcp.2014.11.002

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  32 in total

Review 1.  Medicinal chemistry of adenosine, P2Y and P2X receptors.

Authors:  Kenneth A Jacobson; Christa E Müller
Journal:  Neuropharmacology       Date:  2015-12-12       Impact factor: 5.250

2.  Generation and characterization of polyclonal and monoclonal antibodies to human NTPDase2 including a blocking antibody.

Authors:  Julie Pelletier; Hervé Agonsanou; Ninotchska Delvalle; Michel Fausther; Mabrouka Salem; Brian Gulbransen; Jean Sévigny
Journal:  Purinergic Signal       Date:  2017-04-13       Impact factor: 3.765

3.  Koala and Wombat Gammaherpesviruses Encode the First Known Viral NTPDase Homologs and Are Phylogenetically Divergent from All Known Gammaherpesviruses.

Authors:  Paola K Vaz; Carol A Hartley; Sang-Yong Lee; Fiona M Sansom; Timothy E Adams; Kathryn Stalder; Lesley Pearce; George Lovrecz; Glenn F Browning; Christa E Müller; Joanne M Devlin
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Structure-Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5'-Nucleotidase (CD73) Inhibitors.

Authors:  Anna Junker; Christian Renn; Clemens Dobelmann; Vigneshwaran Namasivayam; Shanu Jain; Karolina Losenkova; Heikki Irjala; Sierra Duca; Ramachandran Balasubramanian; Saibal Chakraborty; Frederik Börgel; Herbert Zimmermann; Gennady G Yegutkin; Christa E Müller; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2019-03-21       Impact factor: 7.446

5.  POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages.

Authors:  Gabriela Pimenta-Dos-Reis; Eduardo José Lopes Torres; Paula Gabriela Quintana; Lincon Onorio Vidal; Bárbara Andréa Fortes Dos Santos; Chuan-Sheng Lin; Norton Heise; Pedro Muanis Persechini; Julieta Schachter
Journal:  Purinergic Signal       Date:  2017-10-11       Impact factor: 3.765

6.  Inhibition of ATP hydrolysis restores airway surface liquid production in cystic fibrosis airway epithelia.

Authors:  Catharina van Heusden; Brian Button; Wayne H Anderson; Agathe Ceppe; Lisa C Morton; Wanda K O'Neal; Hong Dang; Neil E Alexis; Scott Donaldson; Holger Stephan; Richard C Boucher; Eduardo R Lazarowski
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-12-04       Impact factor: 5.464

7.  Induction of antiinflammatory purinergic signaling in activated human iNKT cells.

Authors:  Jennifer C Yu; Gene Lin; Joshua J Field; Joel Linden
Journal:  JCI Insight       Date:  2018-09-06

Review 8.  Adenosine Metabolism: Emerging Concepts for Cancer Therapy.

Authors:  Detlev Boison; Gennady G Yegutkin
Journal:  Cancer Cell       Date:  2019-12-09       Impact factor: 31.743

Review 9.  Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.

Authors:  Sang-Yong Lee; Christa E Müller
Journal:  Medchemcomm       Date:  2017-02-09       Impact factor: 3.597

Review 10.  Purinergic receptors in airway hydration.

Authors:  Eduardo R Lazarowski; Richard C Boucher
Journal:  Biochem Pharmacol       Date:  2021-01-05       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.